BMS587101 - CAS 509083-77-6
Catalog number: 509083-77-6
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C26H20Cl2N4O4S
Molecular Weight:
555.43
COA:
Inquire
Targets:
Lymphocyte function-associated antigen 1(LFA-1)
Description:
BMS-587101 is an LFA-1 small-molecule antagonist. It could reduce inflammation and joint destruction in murine models of arthritis. It inhibited LFA-1–mediated adhesion of T cells to endothelial cells, T cell proliferation, and Th1 cytokine production in vitro. It is developed by Bristol Myers Squibb research. It is used for the treatment of moderate to severe psoriasis. It was in phase II clinical trials, but has been terminated.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Solid powder
Synonyms:
BMS-587101;5-[[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl]methyl]thiophene-3-carboxylic acid
Solubility:
Soluble in DMSO, not in water
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
BMS-587101 is used for the treatment of moderate to severe psoriasis.
Quality Standard:
In-house standard
Quantity:
Milligrams-Grams
Melting Point:
209-230 °C
Density:
748.4±70.0 °C | Condition: Press: 760 Torr
Current Developer:
BMS-587101 is developed by Bristol Myers Squibb research. It was in phase II clinical trials, but has been terminated.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Lymphocyte function-associated antigen 1(LFA-1) Products


BMS587101
(CAS: 509083-77-6)

BMS-587101 is an LFA-1 small-molecule antagonist. It could reduce inflammation and joint destruction in murine models of arthritis. It inhibited LFA-1–mediated ...

Lifitegrast
(CAS: 1025967-78-5)

Lifitegrast is a Lymphocyte Function-Associated Antigen-1(LFA-1) Antagonist. It is used for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It i...

Quick Inquiry

Verification code

Featured Items